Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 百奥赛图 |
|---|---|
| Other Market Stock Code | 688796 |
| H-Share Offer Price | HK$ 25.22 |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Biocytogen-B |
|---|---|
| Stock Code | 02315 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是生物製藥及臨床前研究服務創收公司,業務模式包括藥物開發業務及臨床前研究服務。藥物開發業務包括腫瘤學和自身免疫性疾病治療的研發及抗體開發業務;臨床前研究服務包括基因編輯、臨床前藥理藥效評估及模式動物銷售。 |
| Listing Date | 2022-09-01 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 北京市大興區大興生物醫藥產業基地寶參南街12號院 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.biocytogen.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 25.22 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 12,610 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2022-08-19 to 2022-08-24 |
| Global Offering Shares | 21,758,500 shares |
| HK Public Offer Shares (Initial) | 2,176,000 shares (10.0%) |
| Public Offer Lots (Initial) | 4,352lots (Pool A2,176lots,Pool B2,176lots) |
| International Placing Shares (Initial) | 19,582,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 396,688,420 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 71.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 548,749,370 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 12,610 |
| 2 lots | 1,000 | HK$ 25,220 |
| 3 lots | 1,500 | HK$ 37,830 |
| 4 lots | 2,000 | HK$ 50,440 |
| 5 lots | 2,500 | HK$ 63,050 |
| 6 lots | 3,000 | HK$ 75,660 |
| 7 lots | 3,500 | HK$ 88,270 |
| 8 lots | 4,000 | HK$ 100,880 |
| 9 lots | 4,500 | HK$ 113,490 |
| 10 lots | 5,000 | HK$ 126,100 |
| 12 lots | 6,000 | HK$ 151,320 |
| 14 lots | 7,000 | HK$ 176,540 |
| 16 lots | 8,000 | HK$ 201,760 |
| 18 lots | 9,000 | HK$ 226,980 |
| 20 lots | 10,000 | HK$ 252,200 |
| 30 lots | 15,000 | HK$ 378,300 |
| 40 lots | 20,000 | HK$ 504,400 |
| 50 lots | 25,000 | HK$ 630,500 |
| 60 lots | 30,000 | HK$ 756,600 |
| 70 lots | 35,000 | HK$ 882,700 |
| 80 lots | 40,000 | HK$ 1,008,800 |
| 90 lots | 45,000 | HK$ 1,134,900 |
| 100 lots | 50,000 | HK$ 1,261,000 |
| 120 lots | 60,000 | HK$ 1,513,200 |
| 140 lots | 70,000 | HK$ 1,765,400 |
| 160 lots | 80,000 | HK$ 2,017,600 |
| 200 lots | 100,000 | HK$ 2,522,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 400 lots | 200,000 | HK$ 5,044,000 |
| 600 lots | 300,000 | HK$ 7,566,000 |
| 1,200 lots | 600,000 | HK$ 15,132,000 |
| 1,400 lots | 700,000 | HK$ 17,654,000 |
| 2,176 lots | 1,088,000 | HK$ 27,439,360 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 5.55B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 10,004,481,952 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 2,725,573,822 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 2021年虧損人民幣545.6百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2020 | 2021 |
|---|---|---|
| Revenue | 253,542 | 354,555 |
| Cost of sales | -86,549 | -107,115 |
| Gross profit | 166,993 | 247,440 |
| Other income and gains, net | 27,959 | 35,381 |
| Selling and distribution expenses | -31,656 | -42,032 |
| Administrative expenses | -245,416 | -188,120 |
| Operating profit | -358,426 | -505,816 |
| Net finance costs | -22,537 | -39,425 |
| Share of associates and JVs | 87 | -402 |
| Profit before tax | -476,691 | -545,643 |
| Income tax expense | 0 | 0 |
| Profit for the year | -476,691 | -545,643 |
| Profit attributable to owners | -428,091 | -545,576 |
Balance Sheet
| Item | 2020 | 2021 | 2022-04 |
|---|---|---|---|
| Cash and cash equivalents | 750,044 | 466,445 | |
| Trade and bills receivables | 67,226 | 103,089 | |
| Inventories | 7,980 | 15,140 | |
| Total current assets | 1,147,638 | 874,238 | |
| Total assets | 2,326,518 | 2,302,783 | |
| Total current liabilities | 328,465 | 446,559 | |
| Total liabilities | 868,277 | 1,050,812 | |
| Total equity | 1,458,241 | 1,251,971 | |
| Equity attributable to owners | 1,453,411 | 1,247,208 | |
| Interest-bearing borrowings | 80,918 | 89,799 | 114,055 |
Cash Flow Statement
| Item | 2020 | 2021 | 2022-04 |
|---|---|---|---|
| Net cash from operating activities | -225,313 | -365,778 | |
| Net cash from investing activities | -188,180 | -84,131 | |
| Net cash from financing activities | 868,442 | 219,440 | |
| Net increase in cash | 454,949 | -230,469 | |
| Depreciation of PP&E | 42,493 | 126,481 | 26,534 |
| Amortisation of intangible assets | 874 | 1,616 | 303 |
| Purchase of PP&E | -296,420 | -198,668 | -87,568 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 26.0 |
|---|---|
| First Day Open | HK$ 26.3 |
| First Day Change | 3.09% |
| First Day Volume | 2302000.0 |
| First Day Turnover | 61043900.0 |
| Use of Proceeds | 1、約329.8百萬港元(即所得款項凈額約70%)用于為我們核心產品的進一步臨床研發提供資金;
2、約70.7百萬港元(即所得款項凈額約15%)用于根據我們的千鼠萬抗計劃為抗體藥物發現及開發提供資金;
3、約47.1百萬港元(即所得款項凈額約10%)用于我們其他管線產品的臨床前及臨床開發;
4、約23.6百萬港元(即所得款項凈額約5%)將用作營運資金及其他一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (4)
Joint Bookrunners (8)
Joint Lead Managers (8)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | QuantumPharm Inc. | 76,820,120 HKD | — | 14.00% | — | 6 months | 2023-03-01 |
| 2 | 北京兴星股权投资合伙企业(有限合伙) | 39,191,880 HKD | — | 7.14% | — | 6 months | 2023-03-01 |
| 3 | 荣昌生物制药(烟台)股份有限公司 | 78,383,760 HKD | — | 14.28% | — | 6 months | 2023-03-01 |
| 4 | 三金国际股份有限公司 | 78,383,760 HKD | — | 14.28% | — | 6 months | 2023-03-01 |
| 5 | 维科(香港)经贸有限公司 | 117,588,250 HKD | — | 21.43% | — | 6 months | 2023-03-01 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 沈月雷 | — |
| Company Secretary | 王永亮、區慧晶 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 緊隨全球發售完成後(假設超額配股權未獲行使),主要股東包括:沈博士持股約6.7%;倪博士持股約7.3%;國投上海持股約10.6%;國投深圳持股約4.8%;招銀相關基金合共持股約12.1%;星赫持股約6.6%;百奧維達持股約5.1%;中國人壽持股約5.9%。沈博士與倪博士為配偶及一致行動協議訂約方。 |
|---|




